• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高迁移率族蛋白B1作为骨髓增殖性肿瘤合并动脉粥样硬化的生物标志物。

HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis.

作者信息

Wu Lunbi, Han Dongxue, Zhang Xiaodong, Zhang Shixu, Wang Yicong, Han Wenxue, Jiang Bowen, Chen Huailei, Jiang Libo

机构信息

Qiqihar Medical College, No. 333 Bukui North Street, Qiqihar, Heilongjiang, China.

Department of Laboratory Diagnosis, The Second Affiliated Hospital of Qiqihar Medical College, No. 64, Zhonghua West Road, Qiqihar, 161000, Heilongjiang, China.

出版信息

Eur J Med Res. 2025 May 19;30(1):392. doi: 10.1186/s40001-025-02655-8.

DOI:10.1186/s40001-025-02655-8
PMID:40383792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12087230/
Abstract

OBJECTIVE

The study analyzed the relationship between serum levels of HMGB1 and biochemical indices related to atherosclerosis, clarifying the diagnostic value of HMGB1 in cases of myeloproliferative neoplasm (MPN) accompanied by atherosclerosis (AS).

METHODS

The bone marrow samples and serum were obtained from patients with MPN. qPCR was used to detect the level of HMGN1 mRNA in bone marrow mononuclear cells, while ELISA was used to measure the level of HMGB1 in serum. Additionally, relevant biochemical indices of the patients were collected and the correlation between these indices and HMGB1 levels was assessed.

RESULTS

Compared with the control group, MPN patients exhibited significantly elevated levels of HMGB1 in both bone marrow mononuclear cells and serum. The Pearson correlation analysis revealed a negative correlation between serum HMGB1 levels and both HDL-C and ApoA1. The ROC curve analysis demonstrated that serum HMGB1 had an AUC of 0.929 (P < 0.001) for predicting the complication of AS in MPN patients, with a sensitivity of 100.00% and a specificity of 78.05%. Furthermore, logistic regression analysis showed that serum HMGB1 levels were statistically significant in determining the presence of AS in MPN patients (P < 0.05).

CONCLUSION

Elevated levels of HMGB1 in the bone marrow and serum of MPN patients demonstrate a correlation with biochemical indices related to AS. This finding may serve as a valuable reference for predicting AS complications in MPN patients.

摘要

目的

本研究分析了血清高迁移率族蛋白B1(HMGB1)水平与动脉粥样硬化相关生化指标之间的关系,以阐明HMGB1在伴有动脉粥样硬化(AS)的骨髓增殖性肿瘤(MPN)病例中的诊断价值。

方法

采集MPN患者的骨髓样本和血清。采用qPCR检测骨髓单个核细胞中HMGN1 mRNA水平,采用酶联免疫吸附测定(ELISA)法检测血清中HMGB1水平。此外,收集患者的相关生化指标,并评估这些指标与HMGB1水平之间的相关性。

结果

与对照组相比,MPN患者骨髓单个核细胞和血清中的HMGB1水平均显著升高。Pearson相关性分析显示,血清HMGB1水平与高密度脂蛋白胆固醇(HDL-C)和载脂蛋白A1(ApoA1)均呈负相关。受试者工作特征(ROC)曲线分析表明,血清HMGB1预测MPN患者发生AS并发症的曲线下面积(AUC)为0.929(P < 0.001),敏感性为100.00%,特异性为78.05%。此外,逻辑回归分析显示,血清HMGB1水平在确定MPN患者是否存在AS方面具有统计学意义(P < 0.05)。

结论

MPN患者骨髓和血清中HMGB1水平升高与AS相关生化指标存在相关性。这一发现可为预测MPN患者的AS并发症提供有价值的参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/40cc84d06073/40001_2025_2655_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/2218b0df7791/40001_2025_2655_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/229778b2d465/40001_2025_2655_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/40cc84d06073/40001_2025_2655_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/2218b0df7791/40001_2025_2655_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/229778b2d465/40001_2025_2655_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7826/12087230/40cc84d06073/40001_2025_2655_Fig3_HTML.jpg

相似文献

1
HMGB1 as a biomarker for myeloproliferative neoplasm complicated with atherosclerosis.高迁移率族蛋白B1作为骨髓增殖性肿瘤合并动脉粥样硬化的生物标志物。
Eur J Med Res. 2025 May 19;30(1):392. doi: 10.1186/s40001-025-02655-8.
2
Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.血清高迁移率族蛋白B1水平在子宫颈鳞状细胞癌复发早期检测中的临床价值:与血清鳞状细胞癌抗原、细胞角蛋白19片段和癌胚抗原水平的比较
Croat Med J. 2009 Oct;50(5):455-64. doi: 10.3325/cmj.2009.50.455.
3
Potential Serum HMGB1, HSP90, and S100A9 as Metastasis Predictive Biomarkers for Cancer Patients and Relevant Cytokines: A Pilot Study.血清中潜在的高迁移率族蛋白B1、热休克蛋白90和S100A9作为癌症患者转移预测生物标志物及相关细胞因子:一项初步研究。
Int J Mol Sci. 2024 Dec 10;25(24):13232. doi: 10.3390/ijms252413232.
4
Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.血清高迁移率族蛋白 B1 是胰腺导管腺癌强有力的诊断和预后生物标志物。
Cancer Sci. 2012 Sep;103(9):1714-21. doi: 10.1111/j.1349-7006.2012.02358.x. Epub 2012 Jul 30.
5
Diagnostic significance of serum HMGB1 in colorectal carcinomas.血清高迁移率族蛋白 B1 在结直肠癌中的诊断意义。
PLoS One. 2012;7(4):e34318. doi: 10.1371/journal.pone.0034318. Epub 2012 Apr 4.
6
Evaluation of HMGB1 Expression as a Clinical Biomarker for Cholangiocarcinoma.评估HMGB1表达作为胆管癌临床生物标志物的作用
Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):81-89. doi: 10.21873/cgp.20489.
7
Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma.血清高迁移率族蛋白B1在喉鳞状细胞癌诊断及预后中的临床价值
Med Oncol. 2014 Dec;31(12):316. doi: 10.1007/s12032-014-0316-x. Epub 2014 Nov 6.
8
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms.C-甘露糖基色氨酸是骨髓增生性肿瘤血小板增多症的新型生物标志物。
Sci Rep. 2024 Aug 14;14(1):18858. doi: 10.1038/s41598-024-69496-z.
9
High-mobility group box 1 in multiple sclerosis.多发性硬化症中的高迁移率族蛋白盒1
Immunol Res. 2016 Apr;64(2):385-91. doi: 10.1007/s12026-015-8673-x.
10
HMGB1Modulates the Treg/Th17 Ratio in Atherosclerotic Patients.高迁移率族蛋白B1调节动脉粥样硬化患者的调节性T细胞/辅助性T细胞17比例
J Atheroscler Thromb. 2016 Jun 1;23(6):737-45. doi: 10.5551/jat.31088. Epub 2016 Feb 1.

本文引用的文献

1
Caspase-3/gasdermin-E axis facilitates the progression of coronary artery calcification by inducing the release of high mobility group box protein 1.半胱氨酸天冬氨酸蛋白酶-3/气液蛋白-1 轴通过诱导高迁移率族蛋白 1 的释放促进冠状动脉钙化的进展。
Int Immunopharmacol. 2024 Jan 25;127:111454. doi: 10.1016/j.intimp.2023.111454. Epub 2023 Dec 29.
2
HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases.高迁移率族蛋白 B1 和 Toll 样受体:自身免疫性疾病的潜在治疗靶点。
Mol Med. 2023 Sep 4;29(1):117. doi: 10.1186/s10020-023-00717-3.
3
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
急变期骨髓增殖性肿瘤:当代综述与 2024 年治疗算法。
Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.
4
Mutations, inflammation and phenotype of myeloproliferative neoplasms.骨髓增殖性肿瘤的突变、炎症与表型
Front Oncol. 2023 May 22;13:1196817. doi: 10.3389/fonc.2023.1196817. eCollection 2023.
5
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.高密度脂蛋白功能与动脉粥样硬化:活性二羰基化合物作为有前途的治疗靶点。
Circ Res. 2023 May 26;132(11):1521-1545. doi: 10.1161/CIRCRESAHA.123.321563. Epub 2023 May 25.
6
The Relationship between Circulating APOA-1 and Atherosclerosis Initiation and Progression in Psoriasis.银屑病患者循环 APOA-1 与动脉粥样硬化起始和进展的关系。
J Invest Dermatol. 2023 Oct;143(10):1947-1954.e4. doi: 10.1016/j.jid.2023.01.044. Epub 2023 Apr 22.
7
Elevated branched-chain amino acid promotes atherosclerosis progression by enhancing mitochondrial-to-nuclear HO-disulfide HMGB1 in macrophages.支链氨基酸升高通过增强巨噬细胞中线粒体到核的 HO-二硫键 HMGB1 促进动脉粥样硬化进展。
Redox Biol. 2023 Jun;62:102696. doi: 10.1016/j.redox.2023.102696. Epub 2023 Apr 5.
8
The mechanism of HMGB1 secretion and release.HMGB1分泌与释放的机制。
Exp Mol Med. 2022 Feb;54(2):91-102. doi: 10.1038/s12276-022-00736-w. Epub 2022 Feb 25.
9
Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis.乳酸促进多微生物脓毒症中巨噬细胞 HMGB1 的乳酰化、乙酰化和胞外体释放。
Cell Death Differ. 2022 Jan;29(1):133-146. doi: 10.1038/s41418-021-00841-9. Epub 2021 Aug 6.
10
The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.JAK-STAT 通路:类风湿关节炎和骨髓增殖性肿瘤中心血管疾病的新兴靶点。
Eur Heart J. 2021 Nov 7;42(42):4389-4400. doi: 10.1093/eurheartj/ehab447.